UK markets open in 4 hours 13 minutes
  • NIKKEI 225

    26,374.25
    +220.44 (+0.84%)
     
  • HANG SENG

    21,996.43
    +166.08 (+0.76%)
     
  • CRUDE OIL

    110.62
    +2.19 (+2.02%)
     
  • GOLD FUTURES

    1,810.80
    +9.30 (+0.52%)
     
  • DOW

    31,097.26
    +321.86 (+1.05%)
     
  • BTC-GBP

    16,660.12
    +767.88 (+4.83%)
     
  • CMC Crypto 200

    438.03
    +17.89 (+4.26%)
     
  • ^IXIC

    11,127.84
    +99.14 (+0.90%)
     
  • ^FTAS

    3,967.61
    +27.58 (+0.70%)
     

Unaudited NAV for May 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
Unaudited NAV for May 2022
09-Jun-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

 

Unaudited NAV for May 2022

 

LONDON, 9 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company for date ended 31 May 2022 as follows:

 

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

31-May-22

(unaudited)

£36.6m

£57.8m

£131.3m

£2.7m

£228.4m

 

£1.77

 

 

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:

GB00BD045071

Category Code:

NAV

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

167035

EQS News ID:

1371457


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting